Tfmpp Stats & Data
KKIMDKMETPPURN-UHFFFAOYSA-NPharmacology
DrugBankMetabolism
1-(3-Trifluoromethylphenyl)piperazine has known human metabolites that include HO-TFMPP.
Measured Affinities
Guide to PHARMACOLOGYMeasured binding and functional data for TFMPP, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.
| Target | Action | Measure | Value | Concentration | Species | Source |
|---|---|---|---|---|---|---|
| 5-HT2A receptor HTR2A | Full agonist | pKi | 7.5 | 31.62 nM | Human | PMID 15322733 |
| 5-HT2B receptor HTR2B | Full agonist | pKi | 7.2 | 63.1 nM | Human | PMID 15322733 |
| 5-HT2B receptor Htr2b | Full agonist | pKi | 7.1 | 79.43 nM | Rat | PMID 8450835 |
| 5-HT6 receptor HTR6 | Full agonist | pKi | 6.4 | 398.11 nM | Human | PMID 8522988 |
| 5-HT6 receptor Htr6 | Full agonist | pKi | 6.3 | 501.19 nM | Rat | PMID 7680751 |
| 5-HT7 receptor Htr7 | Antagonist | pKi | 6.3 | 501.19 nM | Mouse | PMID 8394987 |
| 5-HT1F receptor HTR1F | Full agonist | pKi | 6 | 1,000 nM | Human | PMID 8380639 |
| 5-HT5A receptor Htr5a | Full agonist | pKi | 5.6 | 2,512 nM | Mouse | PMID 8450829 |
| 5-HT1B receptor HTR1B | Full agonist | pKi | — | — | Human | — |
| 5-HT1D receptor HTR1D | Full agonist | pKi | — | — | Human | — |
| 5-HT2C receptor HTR2C | Full agonist | pKi | — | — | Human | — |
| 5-HT7 receptor Htr7 | Full agonist | pKi | — | — | Rat | PMID 8394362 |
| 5-ht1e receptor HTR1E | Full agonist | pKi | — | — | Human | — |
Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.
Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.
Effect Profile
CuratedStrong euphoria with strong anxiety/jitters, moderate focus and stimulation
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 19 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 17 of 19
- Not Specified 1 of 19
- Female 1 of 19
Reports Over Time
Dosage Distribution
Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.
Common Combinations
Most co-occurring substances, as a share of all 19 reports filed under Tfmpp
Too few reports for bars: these combinations come from 19 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- BZP 16 of 19
Form / Preparation
Most common forms and preparations, as a share of the 12 reports that give one
Too few reports for bars: these forms come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Powder / Crystals 5 of 12
- Pill / Tablet 5 of 12
- Capsule 2 of 12
Body-Weight Dosing
Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.
Redose Patterns
Redosing behavior across 13 reports
Too few reports for a chart: redosing is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Single dose 9 of 13
- Redosed 4 of 13